“This is the first RSV vaccine approved in the EU that not only protects older adults but also young children from birth,” said EU Health Commissioner Stella Kyriakides in Brussels on Friday. In children, RSV is one of the most common causes of hospitalization in the EU.
The “Abrysvo” vaccine, which has now been approved throughout the EU, is intended to help strengthen the immune response against the virus. According to the EU medicines authority, respiratory diseases caused by the RS virus are usually mild. But especially in small children and particularly vulnerable older adults, there can be a severe or even fatal course. In June, the EU Commission approved the “Arexvy” vaccine against the RS virus – for adults over 60 years of age.